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Introduction: Knowledge of the association of hemodynamics with progression of septic acute kidney injury (AKI)
is limited. However, some recent data suggest that mean arterial pressure (MAP) exceeding current guidelines
(60–65 mmHg) may be needed to prevent AKI. We hypothesized that higher MAP during the first 24 hours in the
intensive care unit (ICU), would be associated with a lower risk of progression of AKI in patients with severe sepsis.
Methods: We identified 423 patients with severe sepsis and electronically recorded continuous hemodynamic data
in the prospective observational FINNAKI study. The primary endpoint was progression of AKI within the first 5 days
of ICU admission defined as new onset or worsening of AKI by the Kidney Disease: Improving Global Outcomes
(KDIGO) criteria. We evaluated the association of hemodynamic variables with this endpoint. We included 53724
10-minute medians of MAP in the analysis. We analysed the ability of time-adjusted MAP to predict progression of
AKI by receiver operating characteristic (ROC) analysis.
Results: Of 423 patients, 153 (36.2%) had progression of AKI. Patients with progression of AKI had significantly
lower time-adjusted MAP, 74.4 mmHg [68.3-80.8], than those without progression, 78.6 mmHg [72.9-85.4], P < 0.001.
A cut-off value of 73 mmHg for time-adjusted MAP best predicted the progression of AKI. Chronic kidney disease,
higher lactate, higher dose of furosemide, use of dobutamine and time-adjusted MAP below 73 mmHg were
independent predictors of progression of AKI.
Conclusions: The findings of this large prospective multicenter observational study suggest that hypotensive
episodes (MAP under 73 mmHg) are associated with progression of AKI in critically ill patients with severe sepsis.Introduction
Both the incidence of severe sepsis and acute kidney in-
jury (AKI) are increasing [1-3]. The incidence of AKI
among patients with severe sepsis is 40 to 50% and
sepsis accounts for half of the cases of AKI in the
intensive care unit (ICU) [1,4-7]. Patients with septic
AKI have worse outcome than septic patients without* Correspondence: erika.wilkman@hus.fi
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higher mortality [6,7].
The understanding of the underlying pathophysiology
of septic AKI is still limited [5,8]. Previously, the reduc-
tion in renal blood flow has been proposed to be essential
for the establishment of AKI [9]. However, this explan-
ation alone is inadequate. The pathogenesis of septic AKI
is complex, involving apoptosis [10], inflammatory re-
sponses, and changes in microcirculation [5,8,11]. The
blood flow to the organs is pressure-dependent outside
the values of the autoregulatory threshold. However, a re-
cent study reported that the autoregulation of renaltral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Figure 1 Flowchart of study patients with severe sepsis with or
without primary endpoint. Primary endpoint = progression of
acute kidney injury (AKI) = new onset of AKI (Kidney Disease:
Improving Global Outcomes (KDIGO) stages 1 to 3, including
initiation of renal replacement therapy) or worsening of AKI by at
least one KDIGO stage during the first 5 days of ICU admission.
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ing AKI, and varies with cardiac output [12].
Current guidelines suggest norepinephrine and fluid
therapy to maintain mean arterial pressure (MAP) ≥60-
65 mmHg for sufficient renal perfusion and prevention
of AKI in critically ill patients [11,13]. However, limited
knowledge exists of the association of hemodynamics,
MAP in particular, with progression of AKI during the
early phase of severe sepsis [14,15]. As other options for
treatment or prevention of AKI are scarce [13], better
knowledge of the association of hemodynamic factors is
essential. We hypothesized that higher MAP would be
independently associated with a lower risk of progres-
sion of AKI.
Accordingly, in this predefined substudy of the prospect-
ive, multicenter FINNAKI study [16], we scrutinized the
associations of hemodynamic variables, especially MAP,
with progression of AKI in patients with severe sepsis.
Materials and methods
The ethics committee of the Helsinki University Hospital
gave approval for the study and for a deferred consent
policy. Written, informed consent was obtained from the
patient or patient’s proxy.
Patients
We identified all patients with severe sepsis and elec-
tronically recorded continuous hemodynamic data from
the prospective observational FINNAKI study that was
conducted in 17 Finnish ICUs between 1 September
2011 and 1 February 2012 [16]. First, we excluded four
ICUs, in which median values of hemodynamic parame-
ters were registered for periods of more than 10 minutes,
or the data on vasoactive treatment were incomplete.
Second, we excluded patients with severe sepsis diag-
nosed later than 24 h after ICU admission. Third, we ex-
cluded patients who died during the first five days in the
ICU (Additional file 1 presents data on these patients) or
who reached the primary endpoint within 12 h after ICU
admission. The numbers of study patients and excluded
patients are presented in Figure 1.
Definitions
We defined severe sepsis according to the American
College of Chest Physicians/Society of Critical Care Medi-
cine (ACCP/SCCM) Consensus Conference Committee
definition [17]. We used the Kidney Disease: Improving
Global Outcomes (KDIGO) criteria to define and stage
AKI according to changes in serum creatinine (SCr) and
urine output [18]. According to KDIGO criteria, AKI is de-
fined by an increase in SCr by ≥26.5 μmol/l within 48 h, or
an increase in SCr ≥1.5 times baseline value, or urine out-
put less than <0.5 ml per kg/h for six hours. We used the
last SCr value from the previous year excluding the weekbefore the ICU admission as baseline SCr, and for those
without a baseline value (n = 292) we estimated it using the
modification in diet in renal disease (MDRD) equation
[19], assuming a glomerular filtration rate (GFR) of 75 ml
per minute/1.73 m2. When available, we also used SCr
values within 48 h before ICU admission to identify the
acute increase in SCr. We defined the primary endpoint
(progression of AKI) as follows: 1) new onset of AKI
(KDIGO stages 1 to 3, including initiation of renal replace-
ment therapy, RRT) or 2) worsening of AKI by at least one
KDIGO stage during the first 5 days of ICU admission.
The negative primary endpoint was defined as absence of
AKI within the first 5 days in the ICU. Chronic kidney dis-
ease (CKD) was defined as structural or functional abnor-
malities of the kidney or GFR <60 ml per minute/1.73 m2
at least one week prior to ICU admission [20]. Hypo-
tension within 48 h prior to ICU admission was defined as
systolic blood pressure <90 mmHg for 1 h and hypovol-
emia according to the judgement of the physician. The
attending physician set the targeted MAP level according
to local practice and current sepsis guidelines [21].
Data collection
We prospectively collected routine data (demographics,
diagnosis by International Classification of Diseases
(ICD-10), ICU scores, physiologic measures, and outcome)
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tained by Tieto Ltd, Helsinki, Finland [16]. Additionally,
we completed a standardized case report form (CRF) at
admission, and daily during days one to five in the
ICU, and at ICU and hospital discharge. The CRF data
comprised data on chronic and present health informa-
tion, risk factors for AKI, severe sepsis, infections and
antimicrobial treatment, organ dysfunction, fluid bal-
ance, and information on RRT [16]. The KDIGO stage was
calculated continuously for each patient based on every
measured creatinine value and hourly urine output [16].
We also prospectively collected data on hemodynamic
measurements and vasopressor and inotrope treatment for
this substudy.
The MAP data were collected into the database as
median values of 2 or 5 minutes depending on the local
patient data management system. Before collection to
the database all data were manually validated for the first
24 hours of ICU admission to eradicate erroneous
values. We converted all MAP data into 10-minute median
values (MAP values) for all analyses.
Data analyses
We first calculated the area under the curve (AUC) for
MAP values using the NCSS 8 software (Kaysville, UT,
USA) by placing the MAP values (10-minute medians)
on the y-axis and time of MAP registrations as 10-minute
periods on the x-axis (see Additional file 2: Figures S1A, B,
and C). We adjusted the MAP AUCs with the total
aggregate time of MAP registrations (that is, the sum of
10-minute periods of MAP median values) for each patient
during the first 24 h (= time-adjusted MAP). For patients
who reached the endpoint within 24 h, MAP registrations
were included in the analysis until the endpoint was
reached. The point of time of the highest AKI stage was
the time of reaching the endpoint. For patients who did
not reach the endpoint within 24 h, MAP values of the first
24 h were included in the analysis.
Second, we calculated the MAP AUC under threshold
values of MAP: 55, 60, 65, 70, 75, 80, 85 mmHg as the
area of MAP and aggregate time of MAP values beneath
each threshold. Third, we calculated the aggregate time
and adjusted aggregate time (percentage) of MAP below
threshold values (55, 60, 65, 70, 75, 80, 85 mmHg) for
each patient. Fourth, we calculated the time-adjusted
MAP deficit below threshold values (55, 60, 65, 70, 75,
80, 85 mmHg) by dividing the MAP AUC below each
threshold value with the total aggregate time of MAP
values for each patient (Additional file 2: Figures S1A, B,
and C). Fifth, we identified patients with time-adjusted
MAP below the best cutoff value for prediction of AKI
progression based on the receiver operating charac-
teristic (ROC) analysis of the time-adjusted MAP. Sixth,
the time-adjusted MAP below this level was used asa categorical variable in the multivariable regression
analysis.
We identified the highest blood lactate value, the low-
est blood pH value and the lowest base excess (BE)
values for each patient for the first 24 h and during days
one to five. The worst values of the first 24 h were used
in the analysis. The highest dose of norepinephrine,
epinephrine, dopamine, dobutamine, and vasopressin
for the first 24 h were used in the analyses. We cal-
culated the vasopressor load using the following for-
mula: vasopressor load (μg/kg/minute) = norepinephrine
(μg/kg/minute) + dopamine (μg/kg/minute/2) + epinephrine
(μg/kg/minute) + phenylephrine (μg/kg/minute/10) [22,23].
In the study ICUs, phenylephrine infusions were not used,
and thus, it was not included in the vasopressor load.
We defined treatment with dobutamine, milrinone or
levosimendan as inotrope treatment, epinephrine was
analyzed as a vasopressor only [24]. We calculated the
time-adjusted fluid balance for the first day in ICU by
dividing the total fluid balance by the number of hours
in the ICU at fluid balance registration. We defined
hydroxyethyl starch (HES) and gelatine as colloids.
Statistical analyses
We present the data as absolute number (percentage) or
median with IQR. For continuous data, we used the
Mann-Whitney U-test for comparison of groups. For
categorical data, we used the chi-square test or Fisher’s
exact test, when appropriate. We analyzed the associ-
ation of hemodynamic data and risk factors for progres-
sion of AKI with the primary endpoint by univariable
analysis. We then included prognostic factors with P <0.2
into a multivariable forward conditional regression analysis
to test the possible independent association with the pri-
mary endpoint. We analyzed the ability of time-adjusted
MAP and highest dose of norepinephrine to predict wors-
ening of AKI by calculating the AUC by ROC analysis with
the primary endpoint. We assessed the best cutoff value by
the Youden Index (sensitivity + specificity −1) [25]. We
performed all statistical analyses using IBM SPSS Statis-
tics 19.0 and 20.0 (IBM, Armonk, NY, USA) or NCSS 8
(Kaysville, UT, USA) software.
Results
Incidence of AKI and progression of AKI
We included 423 patients with severe sepsis in the study
(Figure 1). Of these 423 patients, 153 (36.2%) had AKI
and presented with primary endpoint (progression of
AKI) within 5 days of ICU admission. Patients with pro-
gression of AKI more often suffered from septic shock
(134/153, 87.6%) compared to those without progression
(185/270, 68.5%), P <0.001. They also had CKD, diabetes
mellitus, suffered from hypovolemia and hypotension
prior to ICU admission and had received radiocontrast
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without progression of AKI (Table 1). The 90-day mor-
tality of patients with severe sepsis with progression of
AKI was higher than for patients with severe sepsis with-
out progression of AKI (32.7% versus 18.9%, P = 0.001).
The ICU mortality did not differ significantly between
the groups (7.8% versus 3.3% respectively, P = 0.06).
Of these 423 patients, 102 (24.1%) had new onset of
AKI and 51 (12.1%) had worsening of AKI by at least
one KDIGO stage. The highest AKI stage was based on
changes in SCr in 80.1% (339/423), urine output 13.9%
(59/423) and by initiation of RRT in 25 cases (5.9%). The
progression of AKI is illustrated in Additional file 3. The
median time for reaching the endpoint was 27.0 hours
(16.5 to 45.5 hours). Of 153 patients with progression
of AKI, 66 (43.1%) reached the endpoint on the ad-
mission day, and 50 patients (32.7%) on the second
day in the ICU. RRT was initiated in 34/423 (8%) of the
study patients.
MAP and progression of AKI
We included 53,724 10-minute medians of MAP values
in the calculations. The median aggregate MAP registra-
tion time for patients who fulfilled the endpoint was
1,230 (945 to 1,430) minutes compared to 1,420 (1,350
to 1,440) minutes in those who did not fulfill the end-
point. Patients with progression of AKI had significantly
lower time-adjusted MAP, 74.4 mmHg (68.3 to 80.8),
than those without progression, 78.6 mmHg (72.9 to
85.4), P <0.001 (Additional file 4). The time-adjusted
MAP and aggregate times of MAP values below MAP
thresholds of patients with or without progression of
AKI are presented in Table 2. Except for threshold level
85 mmHg (P = 0.07), the MAP AUC below thresholds
(55 to 80 mmHg) were larger in patients with progression
of AKI than without (P >0.05 for all) (Additional file 5).
The time-adjusted MAP deficits were larger for all thresh-
old levels (55 mmHg and 85 mmHg, P <0.05 for all)
(Additional file 5). The Youden index of the time-adjusted
MAP yielded a cutoff value of 72.7 mmHg for best predic-
tion of AKI progression, (ROC AUC 0.63; CI 95% 0.58
to 0.69), sensitivity 0.44; CI 95% 0.36 to 0.52), specificity
0.76; CI 95% 0.71 to 0.81). The incidence of AKI progres-
sion divided by quintiles of time-adjusted MAP is shown
in Figure 2.
Vasopressor and inotrope treatment
Of the 423 patients with severe sepsis, 311 (73.5%) were
treated with norepinephrine within the first 5 days of
ICU admission, and 293 (69.3%) patients received nor-
epinephrine during the first 24 h in ICU. Patients with
progression of AKI received norepinephrine more often
(P <0.001) during days 1 to 5 in the ICU. The max-
imum dose of norepinephrine was higher both duringthe first 24 h (P <0.001) and within the first 5 days
in the ICU (P <0.001). Patients with progression of AKI
also received inotropes more often than patients with no
AKI progression, 26.1% versus 7.4%, P <0.001. Table 2 pre-
sents details of vasopressor and inotrope treatment.
Patients with progression of AKI by quintiles of high-
est norepinephrine dose are presented in Figure 3. When
patients were divided into quintiles according to time-
adjusted MAP, the highest dose of norepinephrine during
24 h was significantly associated with AKI progression in
the lowest quintile of time-adjusted MAP (47.2 to 69.5
mmHg) (P <0.001), but not in the four higher quintiles
(P = 0.33, P = 0.92, P = 0.16 and P = 0.78 respectively).
The maximum vasopressor load was higher in patients
with progression of AKI than in patients without pro-
gression of AKI (P <0.001).
The Youden index of the highest norepinephrine dose
yielded a cutoff value of 0.19 μg/kg/minute mmHg for
best prediction of AKI progression (ROC AUC 0.66, CI
95% 0.60 to 0.71; sensitivity 0.44, CI 95% 0.37 to 0.52;
specificity 0.80, CI 95% 0.75 to 0.85).
Patients with time-adjusted MAP below 73 mmHg and
highest dose of norepinephrine over 0.19 μg/kg/minute
(42/61 patients, 68.9%) developed AKI more frequently
than patients with time-adjusted MAP over 73 mmHg and
norepinephrine below 0.19 μg/kg/minute (58/226 patients,
25.7%), odds ratio (OR) 6.40, 95% CI 3.45 to 11.89.
Other factors associated with progression of AKI
Of the 423 patients, 68 (16.1%) received HES and 89
(21.0%) received gelatine within 48 h preceding ICU ad-
mission. Within the first 5 days of ICU admission pa-
tients with progression of AKI received colloids (type
not specified) more often than those without (74.5% ver-
sus 59.3%, P = 0.002). The fluid balance on admission
day was significantly higher in patients with progression
of AKI (112.8 ml/h, 7.4 to 216.4 ml/h) than among those
without progression, 51.7 ml/h, −20.5 to 138.6 ml/h),
P <0.001). Patients with progression of AKI had higher
blood lactate levels, lower blood pH levels and lower
BE values than patients without progression both during
the first 24 h and during days 1 to 5 (P <0.001 for all)
(Additional file 6). Hypertension as co-morbidity prior
to ICU admission was not associated with progression
of AKI (P = 0.23). Time-adjusted MAP was higher in
patients with hypertension than in patients without hyper-
tension; 78.5 mmHg (72.7 mmHg to 84.2 mmHg) versus
75.6 (70.3 mmHg to 82.9 mmHg) respectively, P = 0.04).
Multivariable logistic regression analysis
Results of the univariable and multivariable regression
analyses are shown in Table 3.
No significant interaction between time-adjusted MAP
and dose of norepinephrine was detected.
Table 1 Characteristics of patients with severe sepsis with or without progression of AKI
Data available Progression of AKI Data available No progression of AKI P-value
N = 153 N = 270
Age, years 153 64.0 (51.0 to 78.0) 270 63.0 (52.0 to 73.0) 0.1
Gender, male 153 92 (60.1) 270 184 (68.1) 0.1
Baseline creatinine available 153 108 (70.6) 270 184 (68.1) 0.6
Comorbidity
Hypertension 153 81 (52.9) 270 126 (46.7) 0.22
Systolic heart failure or arteriosclerosis 153 30 (19.6) 270 45 (16.7) 0.45
COPD 153 15 (9.8) 270 38 (14.1) 0.2
Chronic kidney disease 153 17 (11.1) 270 7 (2.6) <0.001
Chronic liver disease 153 8 (5.2) 270 12 (4.4) 0.72
Diabetes mellitus 153 42 (27.5) 270 50 (18.5) 0.032
Hypotension prior to ICU 151 64 (42.4) 267 75 (28.1) 0.003
Hypovolemia prior to ICU 151 78 (51.7) 268 96 (35.8) 0.002
Radiocontrast dye prior to ICU 153 44 (28.8) 268 52 (19.4) 0.03
Emergency admission 153 148 (96.7) 270 267 (98.9) 0.12
Operative admission 153 49 (32.0) 270 59 (21.9) 0.02
Community acquired infection 152 76 (50.0) 270 137 (50.7) 0.88
Source of infection
Pulmonary 139 70 (50.4) 246 155 (63.0) 0.02
Abdominal 139 45 (32.4) 246 52 (21.1) 0.02
Genitourinary 139 14 (10.1) 246 12 (4.9) 0.05
Soft tissue 139 14 (10.1) 246 28 (12.4) 0.7
SAPS II points 153 43.0 (35.0 to 55.0) 270 38.0 (30.0 to 46.0) <0.001
SAPS II points without age and renal components 153 24.0 (18.0 to 30.0) 270 24.0 (17.0 to 31.0) 0.7
SOFA D1 points 153 9.0 (7.0 to 11.0) 270 7.0 (5.0 to 9.0) <0.001
SOFA D1 points, without renal points 153 8.0 (6.0 to 10.0) 270 7.0 (5.0 to 9.0) 0.001
During ICU stay
Mechanical ventilation 153 117 (76.5) 270 168 (62.2) 0.003
Use of sepsis corticosteroids 151 55 (36.4) 264 46 (17.4) <0.001
Any vasoactive treatment 153 134 (87.6) 270 181 (67.0) <0.001
Furosemide 153 131 (85.6) 270 189 (70.0) <0.001
Dose of furosemide (iv) per ICU day, mg/day 153 13.6 (3.5-33.9) 270 4.2 (0.0-16.0) <0.001
Aminoglycoside antibiotics 153 1 (0.7) 270 6 (2.2) 0.22
Peptidoglycan antibiotics 153 16 (10.5) 270 29 (10.7) 0.93
ACE inhibitor or ARB 153 10 (6.5) 270 26 (9.6) 0.27
NSAID 153 5 (3.3) 270 17 (6.3) 0.18
Radiocontrast dye 153 15 (9.8) 270 33 (12.2) 0.45
Length of stay
ICU 153 5.7 (3.3 to 10.3) 270 3.8 (2.0 to 7.0) <0.001
Hospital 153 16.0 (9.5 to 26.5) 270 15.0 (9.0 to 23.8) 034
90-day mortality 153 50 (32.7) 270 51 (18.9) 0.001
Values are expressed as median (IQR) or count (percentage). Progression of acute kidney injury (AKI) is defined as onset of new AKI or worsening of AKI by at least
one Kidney Disease: Improving Global Outcomes (KDIGO) stage within the first 5 days after ICU admission. COPD, chronic obstructive pulmonary disease; chronic
kidney disease (CKD) was defined as structural or functional abnormalities of the kidney or glomerular filtration rate (GFR) <60 ml/minute/1.73 m2 at least one
week prior to ICU admission; hypotension, systolic blood pressure <90 mmHg for 1 h; hypovolemia, by judgement of clinicians; SAPS II, simplified acute
physiology score, SOFA D1, sequential organ failure assessment, first score during the ICU stay; iv, intravenous; ACE, angiotensin converting enzyme; ARB,
angiotensin II receptor blocker; NSAID, non-steroidal anti-inflammatory drug.
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Table 2 Time-adjusted mean arterial pressure (MAP) and vasoactive treatments divided by progression of acute
kidney injury
Progression of AKI No progression of AKI P-value
N = 153 N = 270
Time-adjusted MAP 74.4 (68.3 to 80.8) 78.6 (72.9 to 85.4) <0.001
Time-adjusted MAP below 73 mmHg (%) 69 (45.1) 68 (25.2) <0.001
Aggregate time below MAP thresholds, minutes
55 mmHg 0.0 (0.0 to 10.0) 0.0 (0.0 to 10.0) 0.02
60 mmHg 10.0 (0.0 to 70.0) 5.0 (0.0 to 30.0) 0.007
65 mmHg 80.0 (10.0 to 280.0) 50.0 (0.0 to 160.0) 0.02
70 mmHg 290.0 (80.0 to 620.0) 180.0 (40.0 to 480.0) 0.02
75 mmHg 600.0 (235.0 to 985.0) 490.0 (160.0 to 870.0) 0.15
80 mmHg 770.0 (445.0 to 1140.0) 750.0 (287.5 to 1102.5) 0.35
85 mmHg 910.0 (660.0 to 1260.0) 1015.0 (567.5 to 1270.0) 0.86
Time adjusted aggregate time below MAP thresholds, %
55 mmHg 0.0 (0.0 to 1.1) 0.0 (0.0 to 0.7) 0.01
60 mmHg 1.1 (0.0 to 7.2) 0.4 (0.0 to 2.5) 0.002
65 mmHg 7.7 (0.8 to 27.3) 3.6 (0.0 to 11.2) 0.002
70 mmHg 25.4 (7.0 to 59.5) 14.8 (3.4 to 34.6) <0.001
75 mmHg 56.9 (23.0 to 81.9) 37.3 (12.2 to 65.3) <0.001
80 mmHg 76.3 (43.5 to 95.0) 56.5 (24.7 to 80.7) <0.001
85 mmHg 93.1 (65.5 to 97.9) 75.8 (45.8 to 92.8) <0.001
Norepinephrine, n (%) 131 (85.6) 180 (66.7) >0.001
Max dose ≤24 h in ICU (μg/kg/minute) 0.19 (0.07 to 0.42) 0.08 (0.00 to 0.19) <0.001
Max dose 1 to 5 d in ICU (μg/kg/minute) 0.24 (0.11 to 0.50) 0.14 (0.08 to 0.30) <0.001
Epinephrine, n (%) 5 (3.3) 2 (0.7) 0.1
Max dose ≤24 h in ICU (μg/kg/minute) 0.02 (0.02 to 0.02) 0.14 (0.02 to 0.66) 0.31
Max dose 1 to 5 d in ICU (μg/kg/minute) 0.15 (0.02 to 0.15) 0.14 (0.06 to 0.78) 0.8
Dopamine, n (%) 2 (1.3) 2 (0.7) 0.62
Max dose ≤24 h in ICU (μg/kg/minute) 5.0 (2.7 to 5.0) 9.1 (5.56 to 9.1) 0.13
Max dose 1 to 5 d in ICU (μg/kg/minute) 5.0 (2.7 to 5.0) 9.1 (5.56 to 9.1) 0.13
Vasopressor load max (μg/kg/minute)
≤24 h in ICU 0.32 (0.15 to 0.85) 0.14 (0.08 to 0.29) <0.001
1 to 5 d in ICU 0.40 (0.22 to 0.96) 0.15 (0.08 to 0.30) <0.001
Vasopressin, n (%) 4 (2.6) 1 (0.4) 0.06
Dobutamine, n (%) 33 (21.6) 15 (5.6) <0.001
Levosimendan, n (%) 11 (7.2) 4 (1.5) <0.002
Milrinone, n (%) 4 (2.6) 1 (0.4) 0.06
Values are expressed as count (percentage) or median (IQR). The median doses of drug doses are calculated for number of patients receiving aforementioned drug.
AKI, acute kidney injury; AUC, area under the curve; Vasopressor load max (μg/kg/minute) = norepinephrine max (μg/kg/minute) + dopamine max (μg/kg/minute/2) +
epinephrine max (μg/kg/minute).
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MAP was entered to describe MAP. The highest lactate
value during the first 24 h, CKD, daily dose of intraven-
ous furosemide, and time-adjusted MAP per mmHg
(OR 0.96, 95% CI 0.94 to 0.99) remained independent
predictors of progression of AKI.Second, instead of MAP as a continuous covariate, we
tested time-adjusted MAP below the cutoff value of
73 mmHg as a categorical variable. The highest lactate
value during the first 24 h, CKD, daily dose of intraven-
ous furosemide per mg, use of dobutamine during the
first 24 h, and time-adjusted MAP below 73 mmHg
Figure 2 Progression of acute kidney injury (AKI) by quintiles
of time-adjusted mean arterial pressure (MAP). The incidence of
progression of AKI divided in quintiles of time-adjusted MAP presented
for patients with severe sepsis during the first 24 h in the ICU.
Poukkanen et al. Critical Care 2013, 17:R295 Page 7 of 11
http://ccforum.com/content/17/6/R295(OR 2.57, 95% CI 1.48 to 4.46) remained independent
predictors of progression of AKI.
Discussion
In this large prospective multicenter observational study,
progression of AKI occurred in 36% of patients with se-
vere sepsis. CKD, lactate level, dose of intravenous fur-
osemide, use of dobutamine, and lower time-adjusted
MAP or time-adjusted MAP below 73 mmHg were in-
dependently associated with progression of AKI.
Few studies have assessed the relationship of hemo-
dynamics and progression of AKI during early phases ofFigure 3 Progression of acute kidney injury (AKI) by quintiles
of highest dose of norepinephrine. The incidence of progression
of AKI divided in quintiles of highest dose of norepinephrine is
presented for patients with severe sepsis during the first 24 h in
the ICU.severe sepsis [14,15]. Maintaining mean arterial pressure
over 60 to 65 mmHg is currently suggested to maintain
adequate renal blood flow and perfusion [11,13]. How-
ever, the true value of MAP that is beneficial for the kid-
ney is unknown.
In the present study we found that patients with progres-
sion of AKI had significantly lower time-adjusted MAP
(74 mmHg), than those without progression (79 mmHg).
The best cutoff MAP level for prediction of AKI pro-
gression was 73 mmHg. Our finding is in line with re-
cent studies, which have demonstrated that higher MAP
levels than previously recommended may be required to
maintain adequate renal perfusion [14,15]. An experi-
mental study showed similar results in septic pigs [26].
In the subgroup analysis of 127 patients with septic shock
Badin et al. found that patients who developed AKI had
significantly lower time-averaged MAP than those who did
not. The authors concluded that MAP between 72 and 82
mm Hg could be necessary to prevent AKI in patients with
septic shock [14]. In another recent retrospective cohort
study of 274 septic patients, blood pressure was associated
with need for RRT, maximal creatinine concentrations, and
urine output. MAP under 75 mmHg predicted the need
for RRT. Consequently, the authors suggested that for
renal protection, a MAP level of at least 75 mmHg may be
beneficial [15].
There is evidence that lower MAP is associated with
worse outcome in patients with septic shock with AKI
[15,27]. Recently, a small study of cardiac surgery patients
showed that renal oxygen delivery and GFR improved
when MAP was restored from 60 mmHg to 75 mmHg
[28]. Current literature suggests that inflammatory pro-
cesses and changes in renal microcirculation, with subse-
quent uncoupling of systemic and renal blood flow, may
be central processes in the pathophysiology of AKI
[5,8,11]. Renal autoregulation is disturbed during critical
illness and its dependence on cardiac output is increased
[12]. Thus, maintaining adequate renal perfusion to over-
come derangements caused by loss of autoregulation may
be one of the few current therapeutic options for preven-
tion and treatment of AKI.
In the present study, when patients were divided by
level of time-adjusted MAP into quintiles, the highest
dose of norepinephrine was independently associated
with progression of AKI in patients in the lowest quintile
of time-adjusted MAP (47.2 to 69.5 mmHg). Our data
showed that in the lowest quintile, the incidence of AKI
progression increased with increasing doses of norepin-
ephrine. These results may suggest that progression of
AKI is more likely when higher doses of norepinephrine
are required to maintain targeted blood pressure levels
in more severely ill patients with severe sepsis, plausibly
by causing excess constriction of regional vascular beds
[29]. It may also reflect the impact of more severe illness
Table 3 Univariable and multivariable regression analyses for factors associated with progression of AKI in patients
with severe sepsis
Univariable analysis Multivariable analysis








CKD 4.696 (1.901, 11.600) 0.001 6.72 (2.19, 20.63) 0.001 7.24 (2.36, 22.23) 0.001
Diabetes mellitus 1.665 (1.041, 2.662) 0.033 NS NS
Hypotension prior to ICU 1.883 (1.239, 2.863) 0.003 NS NS
Radiocontrast dye prior to ICU 1.677 (1.056, 2.664) 0.029 NS NS
Operative admission 1.685 (1.079, 2.631) 0.022 NS NS
Abdominal infection 1.786 (1.117, 2.855) 0.015 NS NS
SOFA D1 without renal point 1.136 (1.056, 1.223) 0.001 NS NS
Use of sepsis corticosteroids 2.715 (1.715, 4.298) <0.001 NS NS
Use of dobutamine within first 24 h
in the ICU
4.607 (2.259, 9.395) <0.001 2.42 (1.00, 5.81) 0.049 2.68 (1.11, 6.48) 0.028
Norepinephrine max dose 24 h 4.234 (2.036, 8.803) <0.001 NS NS
Daily dose of furosemide (iv, mg) 1.006 (1.002, 1.009) 0.001 1.00 (1.00, 1.01) 0.002 1.01 (1.00, 1.01) 0.001
Fluid balance per hour on D1 in ICU 1.002 (1.000, 1.003) 0.005 NS NS
Lactate 24 h highest 1.374 (1.218, 1.549) <0.001 1.36 (1.18, 1.57) <0.001 1.35 (1.17, 1.55) <0.001
Time-adjusted MAP 0.952 (0.931, 0.973) <0.001 0.96 (0.94, 0.99) 0.006 -
Time-adjusted MAP below 73 mmHg 2.440 (1.602, 3.716) <0.001 - 2.57 (1.48, 4.46) 0.001
CKD, chronic kidney disease defined as structural or functional abnormalities of the kidney or glomerular filtration rate (GFR) <60 ml/miute/1.73 m2 at least one
week prior to ICU admission; hypotension, systolic blood pressure <90 mmHg for 1 h; SOFA D1, sequential organ failure assessment, first score during the ICU
stay; iv, intravenous; MAP, mean arterial pressure; NS, not significant.
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progression of AKI [30].
Norepinephrine is the vasopressor of choice recom-
mended for restoration of MAP in acute circulatory fail-
ure during sepsis [21]. Even though norepinephrine may
have deleterious effects on renal blood flow and renal
function in healthy subjects [31,32], it may increase renal
perfusion and GFR in patients with circulatory failure
[28,33]. However, in an experimental study norepin-
ephrine failed to increase renal microcirculation in
septic pigs, in spite of improved perfusion pressure
[34]. There is also evidence of the association of ad-
verse outcome in septic shock with increasing vaso-
pressor load [23]. As renal blood flow and perfusion
may show individual variation, the evaluation of renal
blood flow, and its distribution and resistive index
has been proposed for finding the optimal MAP tar-
get for each patient [33,35]. With better knowledge
of the individual optimal MAP excessive use of vaso-
pressors may be avoided.
Higher blood lactate, lower pH and lower BE were as-
sociated with progression of AKI indicating, that sys-
temic hypoperfusion was present, even though cardiac
function was not included in this study. Hence, the use
of inotropes may be explained by attempts to increase
insufficient cardiac output in patients with progression ofAKI. However, low BE and pH may also be consequences
of AKI. Recent data indicate that dobutamine may not im-
prove microcirculatory perfusion in septic shock despite an
increase in cardiac index [36]. In addition, some inotropes
may have independent deleterious effects on the septic kid-
ney [37]. In agreement with prospective randomized stud-
ies [38,39] indicating that the use of colloids in the ICU
cause AKI, we also found an association between colloids
and progression of AKI.
This study has some limitations. First, although patient
data were collected prospectively, patients were not ran-
domized to treatment arms targeting different MAP values
or vasopressors, inotropes or fluid treatment. Thus, the as-
sociation of time-adjusted MAP, and time-adjusted MAP
deficits below threshold values, as well as higher vasopres-
sor and fluid load to progression of AKI may partly be ex-
plained by the impact of more severe illness. Second,
exclusion of patients who died during the first five days
may have caused selection bias by elimination of the most
severely ill patients (Additional file 1). However, inclusion
of patients who died would also cause bias. Progression of
AKI and death may be considered as competing risk, as pa-
tients may die before progression of AKI is identified.
Nevertheless, some patients could have died without
progression of AKI. Third, this study focused on MAP
rather than mean perfusion pressure of the kidney, as
Poukkanen et al. Critical Care 2013, 17:R295 Page 9 of 11
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a few patients, and information on IAP levels in the ma-
jority of patients was lacking. Fourth, data on cardiac func-
tion or mixed venous oxygen saturation were collected in
only a minority of patients monitored with a pulmonary
artery catheter. Therefore, the associations between low
cardiac output or low mixed venous oxygen saturation
during the early phase of severe sepsis and progression of
AKI could not be assessed in this study. Finally, during the
FINNAKI study we only collected data on the type of col-
loids received during 48 h prior to ICU admission. There-
fore, we could not assess the association of the use of
colloids, nor on the use of different colloids, particular
HES, with progression of AKI.
Conclusions
In this large prospective study of patients with severe
sepsis, we found that time-adjusted MAP was significantly
lower and independently associated with progression of
AKI in these patients. Our findings suggest that avoiding
hypotensive episodes (MAP under 73 mmHg) may prevent
progression of AKI. This hypothesis should be confirmed
in a prospective randomized trial.
Key messages
 Time-adjusted MAP under 73 mmHg was
associated with progression of AKI in critically ill
patients with severe sepsis
 The highest dose of norepinephrine was not
associated with progression of AKI except in
patients in the lowest quintile (47.2 to 69.5 mmHg)
of time-adjusted MAP
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